NEW YORK, NY / ACCESSWIRE / August 10, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Inotiv, Inc. (NASDAQ:NOTV)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/inotiv-shareholder-loss-submission-form?prid=30753&wire=1
Lead Plaintiff Deadline: August 22, 2022
Class Period: September 21, 2021 - June 13, 2022

Allegations against NOTV include that: (1) Inotiv's acquisition, Envigo RMS, LL ('Envigo'), and Inotiv's Cumberland, Virginia facility (the 'Cumberland Facility') engaged in widespread and flagrant violations of the Animal Welfare Act ('AWA'); (2) Envigo and Inotiv's Cumberland Facility continuously violated the AWA; (3) Envigo and Inotiv did not properly remedy issues with regards to animal welfare at the Cumberland Facility; (4) as a result, Inotiv was likely to face increased scrutiny and governmental action; (5) Inotiv would imminently shut down two facilities, including the Cumberland Facility; (6) Inotiv did not engage in proper due diligence; and (7) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Outset Medical, Inc. (NASDAQ:OM)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/outset-medical-class-action-lawsuit-submission-form?prid=30753&wire=1
Lead Plaintiff Deadline: September 6, 2022
This lawsuit is on behalf of all persons or entities who purchased Outset Medical common stock between September 15, 2020, and June 13, 2022.

Allegations against OM include that: (1) the Company's flagship product, Tablo Hemodialysis System ('Tablo'), would require an additional 510(k) application to be filed with The United States Food and Drug Administration ('FDA'), as defendants had 'continuously made improvements and updates to Tablo over time since its original clearance' (2) as a result, the Company could not conduct a human factors study on a cleared device in accordance with FDA protocols; (3) the Company's inability to conduct the human factors study subjected the Company to the likelihood of the FDA imposing a 'shipment hold' and marketing suspension, leaving the Company unable to sell Tablo for home use; and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and /or lacked a reasonable basis at all relevant times.

Amazon.com, Inc. (NASDAQ:AMZN)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/amazon-com-inc-loss-submission-form-2?prid=30753&wire=1
Lead Plaintiff Deadline: September 6, 2022
This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired shares of Amazon common stock between July 30, 2021, and April 28, 2022, inclusive.

Allegations against AMZN include that: 1) defendants knew or recklessly disregarded that the Company's infrastructure and fulfillment network investments substantially outpaced demand; 2) those investments were a massive, self-imposed, undue drain on Amazon's financial condition; 3) contrary to defendants' public statements and undisclosed to investors, defendants had already implemented cutbacks to Amazon's fulfillment capacity by July 2021; and 4) as a result of defendants' misrepresentations and omissions, Amazon's common stock traded at artificially inflated prices during the class period.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong